-- 据周四在东京证券交易所发布的公告，杏林制药（TYO:4569）将与大东制药（TYO:4577）及其合作伙伴签署谅解备忘录，将其仿制药业务转让给大东制药及其合作伙伴，以将业务重心转向新药研发。 杏林制药计划将其子公司杏林瑞美迪奥（Kyorin Remedio）及其相关生产设施转让给大东制药及其联合投资者将成立的新平台公司，旨在保障日本仿制药市场的稳定供应。 公司此举旨在优先发展新药研发，同时应对仿制药行业面临的结构性挑战，包括盈利能力不足和供应中断等问题。 杏林制药预计将于9月签署最终协议，并计划于2027年4月完成业务转让。
Related Articles
Australia
IonQ, Florida LambdaRail Launch Quantum-Safe Network Initiative
IonQ (IONQ) said Monday it entered an agreement with Florida LambdaRail to develop a nearly 100-mile quantum-safe network from Palm Beach County to Miami-Dade, connecting three research and education institutions.Phase 1 involves creating a three-node corridor linking select area colleges over the existing Florida LambdaRail fiber network before leveraging IonQ's quantum key distribution technology for protection against cyber threats, the company said.Upon completion of phase 1, the initiative is expected to expand across the Florida LambdaRail network, connecting additional institutions statewide, according to a statement.Price: $42.00, Change: $-0.70, Percent Change: -1.63%
$IONQ
Australia
TerrAscend Announces Preliminary First Quarter 2026 Financial Results
TerrAscend (TSND.TO), a North American cannabis operator, announced preliminary and unaudited financial results for the first quarter ended March 31, 2026, on Monday.The preliminary and unaudited financial results reported are from continuing operations, and do not include Michigan, which are reported as discontinued operations effective as of the second quarter ended June 30, 2025, said the company.For the first quarter of 2026, the company expects net revenue of US$65.5 million, compared to US$66.1 million in the fourth quarter of 2025 and US$64.3 million in the first quarter of 2025.It expects gross profit margin of 52.8% for the first quarter of 2026, compared to 52.1% in the fourth quarter of 2025 and 53.9% in the first quarter of 2025.The company's shares were last seen up C$0.03 or 3.3% at C$0.94 on the Toronto Stock Exchange.Price: $0.95, Change: $+0.04, Percent Change: +4.40%
$HMMJ.TO$TSND.TO
International
Dallas Fed April Manufacturing Index Indicates Faster Contraction
The Dallas Fed's monthly manufacturing index fell to a reading of minus 2.3 in April from minus 0.2 in March, compared with expectations for an increase to a reading of 0.8.The index indicates faster contraction, which is in contrast with other regional manufacturing readings already released, and the S&P global flash measure that suggested expansion.For Dallas, there were gains in the readings for production, shipments, new orders, employment and prices paid.The reading for the company outlook rebounded to 3.0 from minus 3.5 in March.